CYP1A1 Primary Antibody
|Aliases||AHH; AHRR; CP11; CYP1; P1-450; P450-C; P450DX|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human CYP1A1 expressed in E. Coli. |
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using CYP1A1 mAb against human CYP1A1 (AA: 203-461) recombinant protein. (Expected MW is 60 kDa)
Figure 2: Immunohistochemical analysis of paraffin-embedded ovarian cancer tissues using CYP1A1 mouse mAb with DAB staining.
Figure 3: Immunohistochemical analysis of paraffin-embedded rectum cancer tissues using CYP1A1 mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
This gene, CYP1A1, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. The gene has been associated with lung cancer risk. A related family member, CYP1A2, is located approximately 25 kb away from CYP1A1 on chromosome 15.
|References (references)||1. Cancer Res. 2009 Apr 1;69(7):2956-65. |
2. Drug Metab Lett. 2009 Jan;3(1):18-27.